Selective cannabinoid-1 receptor blockade significantly benefits fatty acid and triglyceride metabolism in weight-stable nonhuman primates

Vidya Vaidyanathan1*, Raul A. Bastarrachea2*, Paul B. Higgins6, V. Saroja Voruganti2,

Subhash Kamath3, Nicholas V. DiPatrizio4, Daniele Piomelli4,5,

Anthony G. Comuzzie2, Elizabeth J. Parks1,7

1 Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX
2 Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX
3 Department of Medicine/Division of Diabetes, UT Health Science Center at San Antonio, TX
4 Department of Pharmacology, University of California-Irvine School of Medicine, Irvine, CA
5 Unit of Drug Discovery and Development, Italian Institute of Technology, 16163 Genoa, Italy
6 Center for Laboratory Animal Sciences, Crown Bioscience at the David H. Murdock Research Institute, Kannapolis, NC

* These two authors contributed equally to the paper

Running head: Rimonabant in baboons

7 To whom correspondence should be addressed:
Elizabeth Parks, Ph.D. Phone: (214) 648-2054
Center for Human Nutrition Fax: (214) 648-2269
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd., Dallas TX 75390-9052
Email: Elizabeth.Parks@UTsouthwestern.edu

Copyright © 2012 by the American Physiological Society.
Key words: endocannabinoid, adipose, fatty acid flux, stable isotopes, baboon

Abbreviations: AEA, anandamide; 2-AG, 2-arachidonoyl glycerol; B48, apolipoprotein B48; BL, baseline; EC, endocannabinoids; FFA, nonesterified fatty acids; GC/MS, gas chromatography/mass spectroscopy; HPLC/MS, High-performance liquid chromatography/mass spectrometry; OEA, oleoylethanolamide; PEA, palmitoylethanolamide; Ra, rate of appearance; S, Svedberg unit of floatation; SubQ, subcutaneous adipose tissue; TC, total cholesterol; TG, triacylglycerols; TRL, triacylglycerol-rich lipoproteins; VAT, visceral adipose tissue; VLDL, very low-density lipoproteins

Portions of this work were presented at the American Diabetes Association National Meeting in Orlando, FL, 2010.
ABSTRACT

The goal of this study was to determine whether administration of the CB₁-cannabinoid receptor antagonist, rimonabant, would alter fatty acid flux in non-human primates. Five adult baboons (*Papio Sp*), aged 12.1 ± 4.7y (body weight: 31.9 ± 2.1 kg) underwent repeated metabolic tests to determine fatty acid and TG flux before and after 7 wks of treatment with rimonabant (15 mg/d). Animals were fed ad libitum diets and stable isotopes were administered via diet (d₃₁-tripalmitin) and intravenously (¹³C₄-palmitate, ¹³C₁-acetate). Plasma was collected in the fed and fasted states and blood lipids analyzed by GC/MS. DEXA was used to assess body composition and a hyperinsulinemic-euglycemic clamp used to assess insulin-mediated glucose disposal. During the study, no changes were observed in food intake, body weight, plasma and tissue endocannabinoid concentrations, or the quantity of liver-TG fatty acids originating from de novo lipogenesis (19 ± 6% vs 16 ± 5%, for pre- and post-treatment respectively, *P*=0.39). However, waist circumference was significantly reduced 4% in the treated animals (*P*<0.04), glucose disposal increased 30% (*P*=0.03), and FFA turnover increased 37% (*P*=0.02). The faster FFA flux was consistent with a 43% reduction in these fatty acids used for TRL-TG synthesis (40 ± 3% vs 23 ± 4%, *P*=0.02) and 2-fold increase in TRL-TG turnover (1.5 ± 0.9 vs 3.1 ± 1.4 μmol/kg/h, *P*=0.03).

These data support the potential for a strong effect of CB₁ receptor antagonism at the level of adipose tissue resulting in improvements in fasting turnover of fatty acids at the whole body level, central adipose storage, and significant improvements in glucose homeostasis.
INTRODUCTION

The CB₁ cannabinoid receptor (CB₁R) and its endogenous ligands, the endocannabinoids, have emerged as key players in the control of energy balance. Large-scale, randomized, clinical trials of endocannabinoid antagonist treatment (e.g., rimonabant) in humans demonstrated significant improvements in cardiovascular risk factors, although psychiatric side effects caused the drug to be removed from the market [15]. Despite this setback and given the recognition that EC interact with other systems (e.g., inflammation, insulin signaling), research in this area has remained extremely active and peripherally-restricted cannabinoid antagonist-based therapy may still have a place in the improvement of insulin sensitivity. A good deal of recent human research has focused on the tissue distribution, concentrations and peripheral effects of endocannabinoids 2-arachidonoyl glycerol (2-AG) and anandamide (AEA), and the fatty acid ethanolamides, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). The levels of these molecules in plasma and tissue are related to obesity [20; 5], insulin resistance [11], and diabetes [25; 39]. Cannabinoids are lipids that signal through fatty acid means; and a common theme emerging from the basic [25; 39], cellular, and animal research [31; 61] is that their influence on metabolism may be mediated through alterations in fatty acid balance. Early data from rodent studies demonstrated that treatment with an EC agonist elevated liver fatty acid synthesis [41] and that treatment of ob/ob mice with rimonabant reduced hepatic lipogenesis [42]. In humans, obesity is separately associated with elevated plasma endocannabinoid concentrations [24] and increased hepatic de novo fatty acids [54; 23] and thus, whether rimonabant treatment would reduce fatty acid synthesis in an animal model with physiology more close to humans was unknown. Because treatment of human subjects with rimonabant produced weight loss, it has been difficult to separate the beneficial effects of EC antagonist treatment from the metabolic improvements occurring after weight reduction. No tests of fatty acid synthesis or flux had been performed in large animals or humans at weight stability, and metabolic studies available in the literature were often complicated by changes in food intake and body weight. Therefore, the present investigation utilized repeated kinetic analysis to assess the treatment effect of the CB₁ antagonist, rimonabant, on lipid flux in the baboon (Papio) at
weight stability. The close evolutionary relationship between humans and nonhuman primates suggests that they share many of the specific genetic mechanisms involved in determining differential susceptibility to disease [18]. Not only do nonhuman primates offer a large, long-lived animal for the study of chronic diseases associated with metabolic dysregulation [14; 13; 27; 66], they provide a model that is genetically very similar to humans. The present study was designed to test whether the insulin-sensitizing effects of rimonabant would result in a significant reduction in de novo lipogenesis in the baboon and whether improvements in glucose metabolism would be coincident with improvements in adipose lipid flux. The dosage of rimonabant (15 mg/d) was set to not cause a change in food intake, body weight, or produce characteristics of depression in the baboons. As described below, these findings have implications for the role of EC blockade to mediate improvements in metabolic dysfunction through the adipose and support the potential for modulation of the peripheral EC system in the development of future treatments for metabolic diseases.
METHODS

Animals and study design

The baboons studied herein were selected from a population at the Southwest National Primate Research Center located at the Texas Biomedical Research Institute (San Antonio, TX). The overall study design is shown in figure 1. From a larger group of animals (Papio), 5 male baboons were chosen that were 7.5-18.1 yrs of age (i.e., fully sexually mature). Each animal was housed in an individual cage. Given the labor intensive nature of these studies, animals were studied one at a time, sequentially, over a three year period. The light cycle in the clinic room was set every day from 0600 to 1800. During an acclimation phase (fig. 1), each animal was observed for aggressive-submissive behaviors, daily food consumption was monitored, and the animal was accustomed to the tether jacket system [16]. After it was determined that the animal would acclimate to these surroundings, it underwent ketamine sedation and baseline assessments were made as follows: body composition by dual-energy X-ray absorptiometry scan (DEXA, Lunar Prodigy whole body scanner; GE Medical Systems, Madison, WI), measurements of body weight, waist circumference and body surface area, and blood sampling for clinical biochemistries. A hyperinsulinemic-euglycemic clamp study was performed the same day using previously published methods [14; 13]. Following these assessments, the animal underwent surgical tether implantation, as described in detail previously [16]. On the same day, biopsy samples were taken of liver, subcutaneous adipose tissue (SubQ), and omentum, i.e., visceral adipose tissue (VAT). Tissue was frozen in liquid nitrogen immediately after biopsy.

During a 24-h period after catheter placement, the animal was carefully monitored. After a recuperation period of 2 wks, a stable isotope study was performed to quantitate fatty acid and TG flux, as described below. After the isotope study, the animal began treatment with rimonabant (15 mg/d, full form q.d. in the morning) mixed in a peanut butter-based, sweet treat for 7 wks. The dose of rimonabant chosen was based on a pharmacokinetic study performed earlier and chosen to limit weight loss and side effects. At the end of the treatment phase, metabolic study procedures were repeated. Following these studies, the
tether and catheters were removed surgically under isoflurane and the animal monitored again until it recuperated. All study interventions and animal experiments were conducted according to the protocols approved by the Institutional Animal Care and Use Committee (IACUC) from the Texas Biomedical Research Institute. All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

**Dietary intake and isotope labeling scheme**

For all animals, food was made available throughout the study from 0800 through 1600 each day and animals were acclimatized to this feeding time. This protocol was used to obtain a definitive time when animals would have been actively eating (0800 through 1300) to investigate postprandial metabolism. Food intake and changes in behavior (e.g., depressive posture, interactions with handlers) were monitored daily by technical staff. As described in detail elsewhere [4], the standard diet (Monkey Diet 15%, Constant Nutrition Purina 5LE0™) contained carbohydrate 57.7% (g/100g weight), protein 15.3%, fat 4.7% (ether extract). The animals were offered a quantity of food daily that was based on the estimated metabolizable energy requirements for adult captive baboons [17] and designed to meet an expected energy requirement to sustain constant body weight (40-51 kcal * BW in kg). This quantity of energy was adjusted based on the weekly measurements of the animal such that food was provided just in excess of that needed to maintain weight. Water was provided to the animals ad libitum and fresh fruits and vegetables were given for enrichment. Immediately before receiving their food each morning, animals received a single peanut butter sweet treat, which contained the dose of rimonabant. Only on the day of the isotope study was the drug also combined with glyceryl-d<sub>31</sub>-tripalmitin, which allowed for identification of dietary fatty acids in the blood of the animals. The dietary label and the intravenous (IV) isotope studies were performed by modifying human protocols used previously, while taking into account the different metabolic body size of the baboon [33; 62; 63; 4]. At 0800 on the day of the isotope infusion study, an IV infusion of [13C<sub>1</sub>]-sodium acetate (5g dissolved in ½ normal saline, infusion rate of...
1.0 ml/min) was begun to achieve labeling of fatty acids made through the de novo lipogenesis pathway. This infusion continued for 23h. Metabolite and hormone data from the fasting state represent analysis of blood taken before 0800. Blood was drawn at 1100, 1200, and 1300 in the postprandial state, and data presented in tables for the fed state represented the average of these three values. At 1600, the food was removed as per daily protocol. To reduce stress, fasting metabolism in the baboons was assessed at night and under light sedation, as described previously [4]. Accordingly, at 1900, a 0.025 mg/kg bolus dose of midazolam was given, followed by midazolam infusion (0.04 mg/kg/hr) to calm the animal. This light sedation was continued until the end of the isotope study on day 2 at 0700 and the animals rested or slept when the measurements were made. At 2255, an IV infusion of isotopes began which contained \([d_5]\)-glycerol (5mg/kg lean body mass (LBM)/hr) and K\(^+[1,2,3,4-{^13}C_4]\)-palmitate (7µg/kg/min) complexed to human albumin in a ratio of 2:1. During the night, blood was drawn at 2300, 2320, 2340, 2400, 0030, 0100, 0130, 0200, 0300, 0430, 0600, and 0700. All isotopes and the midazolam were infused through a catheter into the femoral vein, and the blood was drawn from the femoral artery, through a different tethered catheter [4]. Isotopes were purchased from Isotec (Miamisburg, Ohio, USA) and from Cambridge Isotope Laboratory (Andover, Massachusetts, USA), were sterile and pyrogen free, and were prepared using sterile technique. Isotopic purity was greater than 98% for all the tracers used.

Analysis of metabolites, hormones, endocannabinoids, and rimonabant

TG-rich lipoproteins (TRL) consisting of chylomicrons and VLDL (d < 1.006 g/L) in the fed and fasted states, were isolated from plasma by ultracentrifugation as described previously [4]. For measurements of plasma-TG, TRL-TG, glucose, and FFA concentrations, enzymatic kits were used (WAKO, #461-09092, #461-08992; WAKO, #439-90901; WAKO, #999-34691, #991-34891, respectively, Richmond, VA). TRL-B48 concentration was measured using a human apoB-48 ELISA kit (Shibayagi, Inc) and insulin was measured by Millipore ELISA kit for human insulin (#EZHI-14K). Systemic rimonabant concentrations in plasma were measured by Sanofi researchers. Briefly, samples from baseline, 3.5-wks, and 7-wks were mixed with 50 µl of internal standard solution (25.0 ng/ml of SR141716-D10 in
acetonitrile). The tubes were vortexed and centrifuged at 10,000 g for 5 min. An aliquot of the
supernatant (50 µl) was transferred into an autosampler vial and mixed with 100 µl of water for
LC/MS/MS analysis. The lower limit of quantitation for SR141716, and its primary metabolite,
SR141715, in samples was 0.25 ng/ml. The endocannabinoids (EC) AEA and 2-AG, and the
anandamide-like fatty acid ethanolamides, OEA and PEA, were measured in plasma and in SubQ and
VAT biopsy samples by HPLC/MS as described previously [26; 22]. Plasma EC concentrations were
measured at baseline, 3.5-wks and 7-wks, while tissue concentrations were measured in biopsy samples
taken at baseline and 7-wks. Liver biopsy samples were used to measure liver-TG content as described
previously [32].

Analysis of fatty acid composition and fatty acid and glycerol turnover

The fatty acid compositions of TRL-TG fatty acids and plasma FFA were analyzed on a HP 6890 series
gas chromatograph as described previously [4]. To determine isotopic enrichments, the GC/MS method
utilized selected ion monitoring for m/z of 270, 271, 272, 274, 300 and 301. Palmitate methyl-ester
enrichments were calculated using 5-point standard curves for M₄ and (d₃₀+d₃₁) analysis. The
measurement of newly-made fatty acids was performed with m/z of 270, 271, 272 and calculated using
the MIDA method [28]. Isotopomers of the propionic ester of glycerol (m/z 171, 172, 173, 175, 176)
were assessed in the EI mode as described by Sunehag [60]. The fragment assessed for the derivatized
d₅-glycerol had an m/z of 173 and the 175/176 ions were derived from the internal standard that was
added (¹³C₃, d₅-glycerol). Comparable ion peak areas between the standard curve and biological samples
were achieved by either diluting or concentrating the sample.

Calculations and statistical analysis

The fatty acid infusate compositions and enrichments were analyzed by GC and GC/MS as described
previously [4]. In the present analysis, palmitate is used as the fatty acid marker for all fatty acids in TG
(i.e., the contribution of plasma palmitate in the FFA pool is assumed to contribute to liver-TG synthesis
as efficiently as other fatty acids in the FFA pool). The contribution of dietary fatty acids to the plasma FFA pool was determined as follows: % FFA from dietary spillover:

\[
\frac{\text{[fraction of } d_{31}\text{-palmitate in FFA]}}{\text{[fraction of } d_{31}\text{-palmitate in the sweet treat-TG]}}
\]

Fasting lipolysis was assessed by measuring the rate of appearance of plasma FFA (RaFFA) and of plasma free glycerol (RaGlycerol) during the night. The final RaFFA and RaGlycerol data for a single baboon was determined from steady-state values collected between 0300 and 0700 (from 4-8h after the start of the infusion). The measurement of TRL-TG turnover, in units of \(\mu\text{mol/kg/h}\), represents the production of lipoprotein-TG from the liver and the clearance of TG from the blood. This turnover was calculated by modeling the rise to plateau of the plasma FFA label (M\(_4\)-palmitate enrichment) in TG over the time frame of 2400 to 0700. To test for changes in TRL-TG assembly in the liver, the variously-labeled methyl-palmitate isotopomers in TG were analyzed as the proportion of total methyl-palmitate found in TG [2]. The values used to obtain these fasted sources were derived from the average contributions of sources in TRL-TG from samples collected between 0400 and 0700. Thus, the contributions of various sources (dietary fat, plasma FFA derived from adipose tissue, and fatty acids made via de novo lipogenesis) of TRL-TG fatty acid are presented here as a proportion, which reflects the fluxes of fatty acids into the intra-hepatic TG synthesis machinery (VLDL-TG synthetic processes). The proportions of palmitate derived from the sources were then multiplied by the absolute concentration of TRL-TG fatty acids to determine their quantitative contributions of these sources to blood-TG concentrations. It is possible that not all fatty acid sources will be identified using this scheme, as we have demonstrated previously [45; 23]. The fatty acids that remain unlabeled at the end of the 23h study could be derived from visceral stores or from intrahepatic-TG droplets. Calculations were performed using Excel (version 2007; Microsoft, Seattle, WA) and statistical analysis conducted using Statview for windows (Version 5.0.1; SAS Institute, Berkeley, CA). Data were tested for skewness and log-transformed when parametric analysis assumptions were not met. For paired t-tests, statistical significance was taken as \(P\)-value of \(\leq 0.05\). Repeated measures ANOVA was used to test BL, 3.5wk and 7wk concentrations of plasma rimonabant concentrations with a \(P\)-value of 0.05 to denote significance.
The association between outcome variables was assessed with Pearson’s correlation coefficients. Simple linear regression was performed using a layered Bonferroni correction for multiple comparisons.
RESULTS

*Morphometric and biochemical changes, concentrations of rimonabant and endocannabinoids (EC)*

Food intake was monitored daily for each animal and was unaffected by rimonabant treatment (data not shown), nor was treatment associated with changes in baboon body weight, body fat, or lean mass (table 1). Waist circumference was reduced 4% starting from 59.0 ± 1.1 cm at baseline, achieving 57.1 ± 0.8 cm at the midpoint of the study (3.5-wks, data not shown), and ending at 56.5 ± 1.9 cm at 7-wks (table 1, P = 0.039). No changes were observed in fasting concentrations of plasma lipids, FFA, ketone bodies, glucose, or insulin. **Figure 2A** displays the concentrations of rimonabant (SR141716) and its primary metabolite (SR141715) in plasma which verifies that the sweet treat containing the compound was a sufficient vehicle for daily drug delivery. Concentrations of both compounds were significantly elevated above the respective baseline levels by 3.5-wks and the 3.5-wk and 7-wk concentrations were not different from one another (**fig. 2A**). The inter-animal variability of concentrations of the metabolite SR 141715 was low compared to the variability of plasma rimonabant between animals. Steady state concentrations were reached for the metabolite, which suggested the capacity for rimonabant metabolism had been maximized. The apparent continued rise of plasma rimonabant concentrations between 3.5- and 7-wks supported the concept of recycling of the compound out of tissues, which would have reached a maximum at 100 days. Indeed, plasma rimonabant concentration at 3.5-wks was significantly associated with total body weight (r = 0.940, P = 0.05), but no significant relationships were detected at 7-wks between plasma rimonabant concentration and any measure of body composition.

Concentrations of the EC AEA and 2-AG, and the anandamide-like, non-CB₁ receptor binding fatty acid ethanolamides, OEA and PEA, were measured in plasma, and in SubQ and VAT (omentum) biopsy samples (BL and 7-wks). To our knowledge, in nonhuman primates, plasma and tissue EC concentrations have not been published before. At baseline, fasting plasma AEA concentrations (2.2 ± 1.3 pmol/mL) were similar to those reported previously in humans [24; 65; 10], as were 2-AG concentrations (45.3 ± 34.6 pmol/mL) [65]. At BL, plasma concentrations of OEA were 16.0 ± 8.7 pmol/mL and PEA, 3.7 ± 0.8
pmol/mL. Within adipose depot types, OEA concentration was significantly higher in VAT (81.0 ± 62.2 pmol/g) compared to SubQ (38.2 ± 41.8 pmol/g, P=0.05). At 7-wk, the higher the SubQ concentrations of OEA and PEA, the greater the animal’s body fat % (fig. 2B-C) and waist circumference (data not shown), while the higher the VAT OEA, the greater the fed TRL-apoB48 concentration (fig 2D), and the higher the VAT PEA, the lower the fasting HDLc concentrations (fig. 2E).

**Glucose disposal, TRL-TG turnover, and kinetic measures of lipolysis**

Treatment with rimonabant for 7-wks did not change fasting glucose concentrations (table 1). However, measurement of glucose disposal rates by the hyperinsulinemic-euglycemic clamp showed a significant 31% increase post-treatment (fig. 3A, P=0.033). Further, the turnover of plasma TG carried in the TG-rich lipoproteins (TRL) increased 2-fold (fig. 3B, P=0.033). Using continuous infusion of both d5-glycerol and 13C4-palmitate, fasting adipose lipolysis rates were measured from midnight through 0700. Although no change in plasma glycerol turnover was observed post-treatment (RaGlycerol, fig. 3C), the rate of appearance of FFA from adipose was 37% higher (fig. 3D, P=0.024). The higher ratio of the FFA and glycerol fluxes suggests that intra-adipocyte fatty acid re-esterification was suppressed by treatment [34]. The concentrations of plasma AEA at BL were positively associated with fasting insulin concentrations (fig. 3E, r = 0.960, P = 0.01), while at 7-wk, plasma AEA concentrations were negatively associated with glucose disposal (fig. 3F, r = - 0.898, P = 0.03).

**Sources of plasma FFA**

Plasma FFA can be derived from adipose tissue release or from TG lipolysis intravascularly. The contributions of these sources to total plasma FFA concentrations over time were identified utilizing the isotopic labeling scheme before after treatment. At BL (fig. 4A, left), total plasma FFA concentrations rose after the onset of eating (open circles between 1000 and 1300) as a result of both a small increase in adipose fatty acids (open triangles) and a large contribution of dietary fatty acids (filled squares). During the night (between 2200 and 0200) total FFA concentrations were surprisingly high and did not return to
fasting levels until 0430. Food was removed from the animal's cage at 1600 yet residual dietary fatty acids were present in the plasma FFA pool throughout the night (fig 4A, filled squares). This could have resulted from either nocturnal release of chylomicrons labeled the previous day (11) or recycling of previously stored label. After treatment with rimonabant (fig. 4A, right), total plasma FFA concentrations again rose postprandially between 1000 and 1300 in a pattern similar to that observed at BL. However, compared to pre-treatment, significantly fewer dietary fatty acids were found in FFA between 1000 and 1300 post-treatment. During the night, diet-derived fatty acids were also lower compared to BL.

**TG concentrations and fatty acid sources used for TG synthesis**

As shown in figure 4C, total plasma-TG concentrations were unchanged by treatment during the fed-state (unfilled vs. filled squares), but during the night, plasma-TG concentrations were lower post-treatment compared to BL. A similar treatment-related reduction was also observed for the nighttime TRL-TG concentrations but the changes did not reach statistical significance (fig. 4C, filled triangles). When the change in nighttime concentrations of plasma-TG was calculated, those animals with the greatest absolute reductions in TG concentrations had the highest rimonabant concentrations in blood ($r = 0.996, P<0.02$). The changes in the nighttime plasma-TG concentrations were due to an increased uptake of the lipids since treatment significantly increased TRL-TG turnover rate (fig. 3B).

The sources of fatty acids used to synthesize TRL-TG, made up primarily of hepatically-derived VLDL during the night, were identified using stable isotope labeling of adipose FFA release, fatty acids made through the de novo lipogenesis pathway in the liver, and fatty acids originating from dietary-TG. Figure 5A presents the analysis of these sources and demonstrates that at BL, of all the fatty acids found in TG, the sources of $75.9 \pm 3.3\%$ of them were identified using the labeling scheme. Of this proportion, dietary sources made up the smallest percentage ($16.2 \pm 4.1\%$) with slightly more coming from de novo lipogenesis and the majority originating from the plasma FFA pool ($40.4 \pm 2.5\%$). Post-treatment, a
smaller proportion of TG fatty acids became labeled (49.5 ± 7.1%, \( P=0.008 \) compared to BL). The relative amounts of dietary and de novo fatty acid represented similar proportions as found at BL (fig. 5A). However, the proportion of TG-fatty acids derived from the plasma FFA pool fell to 57% of the baseline level \( (P=0.009) \).

Lastly, the proportions of TG-fatty acids derived from the sources were multiplied by the total quantity of fasting TRL-TG fatty acids in the blood for each animal to obtain the absolute contributions of these sources to blood-TG (fig. 5B). Fasting TRL-TG fatty acid concentrations were not different between BL and post-treatment (0.90 ± 0.23 and 0.77 ± 0.17 mmol/L, respectively, \( P=0.214 \)), but the absolute amounts of fatty acids identified by labeling was 26% lower after treatment \( (P=0.01) \). Of that labeled, the amount of fatty acids derived from the diet and from de novo lipogenesis were not different after treatment, but the quantity of TRL-TG made from the plasma FFA pool was 46% lower (0.35 ± 0.08 vs. 0.19 ± 0.06 mmol/L, for baseline and post-treatment, respectively, \( P=0.02 \)). After rimonabant, the sources of more TRL-TG fatty acids remained un-identified at the end of the study \( (P=0.01) \). As described above, these fatty acids could have come to the liver through visceral-TG depot release or could have been derived from TG stores within the liver. Indeed, analysis of liver-TG contents from biopsy samples demonstrated an increase in liver stores after treatment (20 ± 2 vs. 35 ± 8 nmol/mg protein at baseline and post-treatment, respectively, \( P=0.046 \)). Plasma rimonabant concentrations did not correlate with the presence of de novo lipogenesis fatty acids, when tested either as a percentage of total TRL-TG or as the absolute quantity derived from lipogenesis. The reduction in TG derived from plasma-FFA was negatively correlated with the plasma rimonabant concentration \( (r = - 0.998, P=0.002) \) - i.e., the higher the plasma rimonabant concentration, the greater the reduction in the use of these plasma FFA for lipoprotein-TG synthesis in the liver.
DISCUSSION

The present investigation utilized kinetic analysis to assess the treatment effect of the CB₁ receptor antagonist, rimonabant, on lipid flux in weight stable, non-human primates. Our hypotheses were 1) that the insulin-sensitizing effects of the drug would reduce lipogenesis in the non-human primate, Papio, as has been demonstrated in mice [19; 41; 42]; and 2) that improvements in glucose metabolism would be coincident with improvements in adipose lipid flux, as previously implicated in rodent studies [49] and in cell-culture [6; 43]. After completion of 7-wks of treatment, rimonabant did not reduce hepatic de novo lipogenesis, which was a surprise. Rather, in the absence of weight loss we observed significant improvements in glucose metabolism, greater whole body turnover and disposal of fatty acids and TG, and a significant metabolic impact of the drug evident during the night which included more efficient disposal of dietary fatty acids consumed the previous day. As described below, these findings have implications for the role of CB₁R blockade to mediate improvements in metabolic dysfunction through the adipose and support the potential for modulation of the peripheral EC system in the development of future treatments for metabolic diseases.

In the baboon studies here, although rimonabant treatment did not change EC concentrations in plasma or adipose tissues, treatment uncovered significant relationships between the ECs and lipid-related variables similar to relationships previously observed in humans [21] At BL plasma AEA concentrations were elevated in those animals with higher fasting insulin concentrations, while after treatment, higher AEA concentrations were associated with lower glucose disposal rates (\(P<0.05\)). Furthermore, post-treatment, higher concentrations of SubQ and VAT OEA and PEA were tightly associated (\(r > 0.75\)) with greater amounts of adipose mass, a finding similar to that of Gonthier and colleagues, who showed that PEA is the ethanolamide secreted in the highest concentration from human primary adipocytes in culture [37; 27; 30]. In line with the ethanolamides’ role in metabolic dysfunction, baboon VAT OEA and PEA concentrations were associated with higher fed-state concentrations of intestinal lipoproteins in plasma (apoB48 concentrations), and lower HDLc concentrations (fig. 2E). That these associations were present
only after 7-wks (and not at BL) is likely due to the uniformity of the conditions of housing in the clinic (same feeding time for all the animals, common diet, reduced physical activity, etc.). These observations support a negative influence of the cannabinoid system on lipid metabolism and underscore the similarities of the EC/insulin sensitivity axis between baboons and humans [21].

The first of our hypotheses was that hepatic lipogenesis would be significantly reduced after rimonabant treatment, even at weight stability. This hypothesis was based on much data from rodent studies demonstrating that treatment with an EC agonist elevated liver fatty acid synthesis [41], that the liver CB₁R in mice is required for stimulation of fatty acid synthesis during high-fat feeding, and that treatment of ob/ob mice with rimonabant reduced hepatic lipogenesis [42]. In humans, obesity is separately associated with elevated plasma endocannabinoid concentrations [24] and increased hepatic de novo fatty acids, as evidenced by analysis of liver-TG directly [23; 48], and of VLDL-TG, a validated marker of hepatic lipogenesis [54; 23]. Analyzing the presence of newly-made fatty acids in VLDL-TG before and after treatment, we found no significant differences. Our lack of ability to detect a change in lipogenesis was not due to low basal levels of fatty acid synthesis. Compared to humans in which fasting lipogenesis contributes 0-12% of VLDL-TG palmitate, baboons exhibited higher levels (19%) presumably due to the higher content of carbohydrate in their diet (69% of total dietary energy). The lack of treatment-induced changes in lipogenesis observed here suggest the role of the EC system to increase lipogenesis in rodents, and the beneficial effect of rimonabant to reduce lipogenesis, are dependent on alterations in food intake. It is well established that lipogenesis is a process exquisitely sensitive to negative energy balance [55; 28].

The second key finding of the present study was a rimonabant-induced improvement in macronutrient metabolism at multiple physiologic levels. Bluher et al showed that high plasma 2-AG concentrations correlated negatively with glucose disposal rates in humans [10] as we have found here in baboons (fig. 3F). Further, the 30% improvement in glucose disposal rates during the clamp echoes significant
reductions in 2-h glucose post-OGTT found in humans, although the latter occurred against a backdrop of body weight loss [52]. From a lipid metabolism perspective, a 37% increase in plasma FFA turnover was observed after treatment (fig. 3D), which is consistent with a growing body of research. Evidence of a role for EC to modulate adipose tissue metabolism includes the discovery of cannabinoid receptors, CB1R and CB2R, in human omental and SubQ adipocytes [51], increased glucose uptake into adipocytes and lipid droplet formation following CB1R stimulation [36], and abrogation of the latter effect by CB1R antagonism in primary human adipocytes [43]. In the baboons, the combined turnover data from both plasma glycerol and FFA suggested that rimonabant reduced adipose reesterification rates resulting in greater outflow of FFA from adipose. Furthermore, the baboon’s waist circumferences became significantly reduced with treatment. Redistribution of body fat, in the absence of loss of total body weight has been observed before with other insulin sensitizers such as pioglitazone [57; 38]. Although rimonabant-induced weight loss in humans has resulted in reductions in waist circumference [15], the observations here were completely unanticipated due to the constancy of the animals’ body weights. On the other hand, in accord with our findings, Richey et al reported that 16-wks of rimonabant treatment in high-fat fed dogs reduced subcutaneous adipose tissue accumulation by 20% and also prevented a diet-induced expansion of visceral adipose fat [50].

The present kinetic data suggest that the reductions in adipose accumulation in mice and dogs observed previously were due to a stimulation of fatty acid release from adipose as a result of lower reesterification intracellularly. Whether the impact of rimonabant on adipose metabolism is direct in primates and/or humans remains an open question [64]. Early data from treated mice suggested that peripheral modulation by CB1R antagonism was not a major mechanism for anti-obesity effects [46; 47; 59; 56]. However, in addition to the research cited above, numerous recent studies from primary cell culture [25; 39] and tissue expression analysis [51; 43] provide evidence that CB1R antagonists can exert their effects directly through adipocyte signaling [35], as reviewed elsewhere [44]. Compared to central administration, intraperitoneal administration of rimonabant in rats led to independent effects of lipid
mobilization in white adipose tissue [40] and Osei-Hyiaman et al have clearly shown that in mice, hepatic specific deletion of the CB$_1$R protects against diet-induced steatosis [42]. Hence, one limitation of the present study is that it cannot be definitively determined whether the beneficial effects of treatment to change adipose metabolism were direct or mediated centrally. A test of the true direct effect of endocannabinoid antagonists on peripheral metabolism in vivo will await the development of compounds that do not cross the blood brain barrier. Of note, the main limitations of this study are the small sample size that characterizes primate studies, a lack of control group, and the requisite isolation of the animals outside their typical social structure (required for the metabolic studies). These characteristics of the study design raise the issue of whether clinic housing alone would change any of these measures. Observations from animals kept in similar housing conditions suggest some variability in waist circumference over time, and that metabolic markers such as insulin and FFA may worsen due to stress (Parks, Bastarrachea, unpublished observations) – if the latter two observations are reproducible, the present findings would be even more significant. Other study limitations include the measurement of whole-body adipose tissue fatty acid release rather than depot-specific fatty acid release in vivo and a lack of direct measurement of visceral-TG stores. Nonetheless, given the intensive nature of tracer studies, particularly in primates, the present results contribute important new findings of a dominant influence of the drug on adipose fatty acid and plasma TG turnover.

The third finding of this study was a significant increase in the plasma turnover of TG-rich lipoprotein particles in treated baboons. In humans, high plasma 2-AG concentrations correlate positively with serum-TG concentrations [10] and SubQ levels of AEA, OEA and PEA correlated negatively with SubQ lipoprotein lipase activity [1] which would serve to reduce TG clearance from plasma. In mice, chemically-induced elevations in endogenously-produced EC slow TG clearance--an effect that was absent in CB$_1$ KO mice [53]. In the treated baboons, the faster TG turnover equates to greater clearance of lipid from plasma and was also substantiated by a reduced presence of dietary fatty acids in the plasma FFA pool both postprandially and in the middle of the night (fig. 4A/B). Such spillover of chylomicron-
derived fatty acids occurs when lipoprotein lipase activity outpaces tissue uptake [3]. The significant relationship observed between VAT EC and fasting and fed TRL-B48 concentrations highlight recent discoveries regarding the role of EC metabolism and intestinal lipid absorption [22]. Whether EC antagonism impacts intestinal lipid absorption and clearance via endocrine and/or paracrine effects will be important to determine. The significant positive relationships observed between body fat and SubQ levels of OEA and PEA (fig. 2B/C) suggest that the ethanolamides, being fat derived, may provide a global signal of elevations in fat storage. Since increased body fat is associated with enhanced inflammation, the increased levels of the potent anti-inflammatory PEA [30] may be evidence of a counter-regulatory response that is proportional to body fat content. Collectively, these data provide a metabolic connection to systematically link the mounting basic evidence of the control of the EC system on adipocyte [29], skeletal muscle [58], and intestinal biology [22] to impair lipid metabolism. Recent reports have also described the presence of both cannabinoid CB1 and CB2 receptors in rat pancreatic beta cells [9; 7] and in isolated human islets [8], adding the endocrine pancreas as a potential site in the regulation of glucose homeostasis and indicating a functional a role for endogenous endocannabinoid signaling in regulation of endocrine secretion in the pancreas. These data extend the strong congruence of evidence from various animal models supporting a principal role of the EC system to improve insulin sensitivity through mechanisms of lipid flux.

The fourth finding of this study involves the effect of rimonabant to lower the proportion of VLDL-TG fatty acids becoming labeled during the 23h of stable isotope administration (fig. 5). We have shown previously that the contribution of fatty acid sources used for synthesis of plasma VLDL-TG mirror the contributions made to liver-TG pools assessed by biopsy [23]. Thus, the increase in the “unlabeled fatty acid pool” seen in VLDL-TG post-treatment would suggest that the particles were assembled using either greater proportions of stored (cold) liver-TG, or fatty acids derived from visceral-TG stores which were released to the liver. We speculate that both mechanisms may have been in play since although liver-TG increased significantly, it did not rise to levels of fatty liver, while the animal’s waist circumferences
became significantly (4%) reduced post-treatment. A number of other independent observations also support this concept and include faster FFA turnover (fig. 3D), the lower proportional and absolute lipoprotein-TG fatty acids labeled with the plasma FFA isotope indicating liver synthesis of VLDL-TG used almost ½ as many plasma FFA (fig. 5A/B), lower dietary spillover of chylomicrons fatty acids (fig. 4A/B), and no change (or potentially even lower) plasma FFA concentrations, which combined provide evidence of greater clearance of FFA peripherally to organs other than liver (e.g., muscle and heart). The mechanism(s) by which rimonabant could improve fatty acid clearance peripherally are currently unknown, but could include an increase in energy expenditure [12; 29].

In summary, the present study is the first to demonstrate in weight-stable animals, the dominant effect of improved fatty acid kinetics as a result of treatment with an EC antagonist. Data from body composition, morphometrics, multiple isotope kinetics, and measurement of plasma and tissue cannabinoids provide direct evidence to support the hypothesis that antagonism of cannabinoid receptor signaling controls fat storage by regulating lipolysis, and that improvement in fatty acid and TG disposal in the fasted and fed states provides the metabolic means to improve insulin sensitivity. It is unknown whether these changes were due to a direct effect of rimonabant on adipose tissue, due to an indirect effect orchestrated through neural circuits, or a combination of both of these mechanisms. However, the improvements in metabolic health in the absence of weight loss suggest that development of new antagonists that do not cross the blood brain barrier have potential as future treatments for insulin resistance and diabetes. Lastly, the significant relationships observed here between plasma/adipose tissue concentrations of EC and measures of body composition and insulin sensitivity were similar to those observed in humans. These results underscore the strength of the non-human primate model in investigating pathways of energy metabolism that have relevance to human disease.
ACKNOWLEDGMENTS

The authors would like to express their appreciation to the veterinarian technicians and the staff at the Texas Biomedical Research Institute (Texas Biomed) for their excellent care of the animals. In addition, we are grateful to Vicki Mattern at Texas Biomed and Sonya Veron, UT Southwestern, for expert technical assistance, to Patricia Tramontanato, Raju Amin, and Yongi Lou (Sanofi) for discussions of the study design and measurements of plasma rimonabant, and to Dr. Franco Folli at UTHSCSA for advice on data interpretation.

GRANTS

This study was funded by an unrestricted grant from Sanofi and the investigation was conducted in facilities constructed with support from the Research Facilities Improvement Program under grant number C06 RR (# 014578, 013556, 015456, 017515) from the National Center for Research Resources, National Institute of Health, and with support from NIH grants PO1HL028972, and P51RR013986.

CONTRIBUTIONS OF AUTHORS

V. Vaidyanathan Performed study, generated and analyzed data, wrote manuscript.
R.A. Bastarrachea designed the study, generated/analyzed data, and contributed to the interpretation of all findings.
P.B. Higgins contributed to the study design and collected data.
V.S. Voruganti contributed to the study design and collected data.
S. Kamath contributed to data collection and interpretation.
N.V. DiPatrizio contributed to data collection and interpretation.
D. Piomelli contributed to data interpretation.
A.G. Comuzzie contributed to the study design and interpretation of the findings.
E.J. Parks designed the study, generated and analyzed data, wrote manuscript.

CONFLICT OF INTEREST STATEMENTS

The authors have no conflicts of interest.
REFERENCES


Table 1

* Treatment group, n=5 male baboons and reference animals include 2 male baboons. Values are mean ± SEM; Paired t-tests were used to test for significant differences. Plasma-TG and TRL-TG values were log transformed before analysis. Values are of fasting metabolites derived from the first blood draw on the morning of the isotope infusion study. HDLc, high density lipoprotein cholesterol; TRL, TG-rich lipoproteins; B48, apolipoprotein B48.
FIGURE LEGENDS

Figure 1. Study timeline
Five male baboons were studied over a 12-wk period to determine the effect of 15 mg/kg per day of the CB₁ antagonist, rimonabant. For details of procedures, see methods section.

Figure 2. Plasma concentrations of rimonabant and its primary metabolite and the association between subcutaneous OEA and PEA and body fat
Values are mean ± SEM. A) Plasma concentrations of rimonabant (SR141716) and its primary metabolite (SR141715) at baseline, 3.5 wks and 7 wks post-treatment in 4 baboons. For both the drug and its metabolite, concentrations at 3.5 and 7 wks were significantly greater (P<0.05) than their respective concentrations at baseline (i.e., before drug treatment). Relationships were explored between 7-wks concentrations of subcutaneous adipose tissue (SubQ) oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) and body fat content (%), panel B and C, respectively. At 7-wks, higher visceral adipose tissue (VAT) OEA (panel D) and PEA (panel E) concentrations were associated with greater TRL-apoB48 lower and HDLc, respectively.

Figure 3. Changes in metabolic variables over time
Figure 3 A-D (n=5) reflecting (A) changes in glucose disposal rates, (B) TG-rich lipoprotein (TRL)-TG turnover, (C) rates of appearance of plasma glycerol, RaGlycerol, and (D) RaFFA. The asterisks denote significant differences from the corresponding baseline (BL) time points. Relationships were explored between (E) BL fasting plasma anandamide (AEA) concentrations and fasting plasma insulin and (F) post-treatment AEA and glucose disposal rates (Rd) in both untreated baboons (open triangles) and treated (filled triangles) baboons.

Figure 4. Sources of plasma FFA and concentrations of plasma-TG and TRL-TG
Top figure: Total concentrations and sources of plasma FFA (n=5) over 23-h at BL (A) and post-treatment (B) with error bars removed for visual clarity. Figure symbols are: circles, total plasma FFA concentrations; triangles, plasma FFA derived from adipose release; squares, plasma FFA derived from dietary TG-fatty acids. Bottom figure (C): Concentrations of total plasma-TG (upper data, symbols are squares) and TRL-TG (lower data, symbols are triangles) over 24-h at BL (unfilled symbols) and post-treatment (filled symbols). Food was made available to the animals from 0800 to 1600 each day. The asterisks denote significant differences from the corresponding BL time points.

Figure 5. Fractional and absolute quantity of TRL-TG fatty acid sources identified by isotopic labeling

Data represent the contribution of TRL-TG fatty acids derived from the adipose, via the plasma FFA pool (stippled bars), from carbohydrates via hepatic de novo lipogenesis (solid filled bars), from dietary TG (hatched bars), and for fatty acids not labeled (source unidentified) during the course of the 23-h experiment (open bars). The sources of fatty acids are presented as they contributed (A) proportionally to TRL-TG synthesis, and (B) to the absolute synthesis of TRL-TG. The total amount of fatty acid sources accounted for using the isotopic labeling scheme were found to be different whether the data were considered in units of % (P=0.008) or mmol/L (P=0.01).
## Animal Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>7 wks</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometrics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>31.6 ± 1.1</td>
<td>31.2 ± 1.6</td>
<td>0.141</td>
</tr>
<tr>
<td>Body fat mass (kg)</td>
<td>2.7 ± 0.6</td>
<td>2.5 ± 0.6</td>
<td>0.302</td>
</tr>
<tr>
<td>Body fat mass (%)</td>
<td>8.7 ± 1.8</td>
<td>7.8 ± 1.6</td>
<td>0.256</td>
</tr>
<tr>
<td>Lean mass (kg)</td>
<td>27.7 ± 0.5</td>
<td>27.4 ± 0.5</td>
<td>0.293</td>
</tr>
<tr>
<td>Lean mass (%)</td>
<td>88.4 ± 1.6</td>
<td>89.6 ± 0.9</td>
<td>0.486</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>59.0 ± 1.1</td>
<td>56.5 ± 1.9</td>
<td><strong>0.039</strong></td>
</tr>
<tr>
<td>Trunk fat (kg)</td>
<td>1.59 ± 0.56</td>
<td>1.12 ± 0.30</td>
<td>0.257</td>
</tr>
<tr>
<td>TRL-TG (mmol/L)</td>
<td>0.11 ± 0.03</td>
<td>0.12 ± 0.06</td>
<td>0.372</td>
</tr>
<tr>
<td>TRL-B48 (ng/mL)</td>
<td>118 ± 47</td>
<td>114 ± 13</td>
<td>0.472</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>7.9 ± 3.4</td>
<td>6.2 ± 2.3</td>
<td>0.298</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>4.8 ± 0.2</td>
<td>5.0 ± 0.2</td>
<td>0.195</td>
</tr>
<tr>
<td>FFA (mmol/L)</td>
<td>0.45 ± 0.09</td>
<td>0.37 ± 0.07</td>
<td>0.170</td>
</tr>
<tr>
<td>Ketone bodies (µmol/L)</td>
<td>94 ± 26</td>
<td>89 ± 16</td>
<td>0.312</td>
</tr>
</tbody>
</table>
Prescreening adult baboons
Anthropometrics
Blood chemistry

Week 0
Place cannula

Weeks 3-4
Morphometrics
DEXA
Clamp
Blood chemistry

Week 4
Isotope study

Week 5
Begin treatment

Week 8
Blood chemistry

Week 11
Morphometrics
DEXA
Clamp
Blood chemistry

Week 12
Isotope study

Admit to clinic: Acclimate to tether system, n=5, maintain on chow

Rimonabant (15 mg/d) in sweet treat (1/day)

Remove cannula
Discharge
Figure 2

A

Compound (ng/mL plasma)

Time (weeks)

SubQ PEA

SubQ OEA

r = 0.971  
P = 0.006

r = 0.895  
P = 0.04

B

Body fat (%)  
SubQ OEA (pmol/g)

C

Body fat (%)  
SubQ PEA (pmol/g)

D

Fed TRL-apoB48 (mg/mL)  
VAT OEA (pmol/g)

E

HDLc (mg/dL)  
VAT PEA (pmol/g)

r = - 0.894  
P = 0.04
Figure 3

A. Glucose disposal rates

![Graph showing glucose disposal rates with BL and Post-treatment bars.

B. TRL-TG turnover rate

![Graph showing TRL-TG turnover rate with BL and Post-treatment bars.

C. Glycerol turnover rate

![Graph showing glycerol turnover rate with BL and Post-treatment bars.

D. FFA turnover rate

![Graph showing FFA turnover rate with BL and Post-treatment bars.

E. BL Plasma AEA & Insulin

![Graph showing the correlation between BL Fasting Insulin (mU/mL) and Plasma AEA (pmol/mL) with a correlation coefficient of r = 0.960 and P = 0.01.

F. 7-wk Plasma AEA & Rd

![Graph showing the correlation between 7-wk Fasting Glucose Rd and Plasma AEA (pmol/mL) with a correlation coefficient of r = -0.898 and P = 0.03.]}
**Figure 4**

**A. FFA Baseline**

- **Food available**
- **Total plasma FFA**
- **Adipose derived**
- **Diet derived**

**B. FFA Post-treatment**

- **Food available**

**C. TG concentrations**

- **Plasma-TG**
  - Baseline
  - Post-treatment

- **TRL-TG**
  - Baseline
  - Post-treatment

**Military time (h)**

- 0 20 40 60 80 100
- 6 8 10 12 14 22 24 2 4 6 8

**FFA (mmol/L)**

- 0.00 0.20 0.40 0.60 0.80 1.00

**TG concentration (mg/dL)**

- 0 20 40 60 80 100

* * *

* *

**Food available**
Figure 5

Unidentified
Dietary
De novo lipogenesis
FFA

A

Fraction of TRL-TG fatty acid sources

Baseline
Post-treatment

P = 0.008

24.1 ± 5.1%
16.2 ± 4.1%
19.4 ± 6.0%
40.4 ± 2.5%

50.5 ± 6.0%
16.4 ± 5.3%

P = 0.009

23.2 ± 4.6%

Baseline
Post-treatment

P = 0.02

0.35 ± 0.08
0.19 ± 0.06

0.37 ± 0.05
0.14 ± 0.06

0.20 ± 0.09
0.14 ± 0.06

0.22 ± 0.08
0.14 ± 0.06

0.08 ± 0.02
0.14 ± 0.06

Baseline
Post-treatment

P = 0.01

0.14 ± 0.05
0.08 ± 0.02

0.14 ± 0.06

0.14 ± 0.06

0.08 ± 0.02

P = 0.009

50.5 ± 6.0%
16.4 ± 5.3%

19.4 ± 6.0%

23.2 ± 4.6%

9.9 ± 0.8%

Baseline
Post-treatment

40.4 ± 2.5%

Baseline
Post-treatment

24.1 ± 5.1%
16.4 ± 5.3%
19.4 ± 6.0%
23.2 ± 4.6%